The U.S. Food and Drug Administration today expanded the indication for Symdeko (a combination of tezacaftor/ivacaftor) tablets for treatment of pediatric patients ages 6 years and older with cystic fibrosis who have certain genetic mutations.
from https://www.news-medical.net/news/20190622/FDA-expands-approval-of-cystic-fibrosis-treatment-to-include-pediatric-patients-as-young-as-6-years-old.aspx
from
https://healthnews010.tumblr.com/post/185809390913
No comments:
Post a Comment